AbbVie Inc.
07/03/2024 | Press release | Distributed by Public on 07/03/2024 12:08
Results of Operations and Financial Condition Form 8 K
AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
| (in millions, except per share data) | Quarter Ended June 30, 2024 | Full-Year Ended December 31, 2024 | ||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | |||||||||
| Low | High | Low | High | |||||||||
| Previously announced guidance excluding Q2 2024 acquired IPR&D and milestones expense | $ | - | $ | 3.05 | $ | 3.09 | $ | 164 | $ | 11.13 | $ | 11.33 |
| Q2 2024 acquired IPR&D and milestones expense | 937 | (0.52) | (0.52) | 937 | (0.52) | (0.52) | ||||||
|
Guidance including Q2 2024 acquired IPR&D and milestones expensea
|
$ | 937 | $ | 2.53 | $ | 2.57 | $ | 1,101 | $ | 10.61 | $ | 10.81 |
a The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.
1